IMUX
Price
$0.58
Change
+$0.01 (+1.75%)
Updated
Dec 24 closing price
Capitalization
70.28M
55 days until earnings call
Intraday BUY SELL Signals
RGNX
Price
$14.46
Change
+$0.11 (+0.77%)
Updated
Dec 24 closing price
Capitalization
732.01M
67 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IMUX vs RGNX

Header iconIMUX vs RGNX Comparison
Open Charts IMUX vs RGNXBanner chart's image
Immunic
Price$0.58
Change+$0.01 (+1.75%)
Volume$777.05K
Capitalization70.28M
REGENXBIO
Price$14.46
Change+$0.11 (+0.77%)
Volume$191.16K
Capitalization732.01M
IMUX vs RGNX Comparison Chart in %
IMUX
Daily Signal:
Gain/Loss:
RGNX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
IMUX vs. RGNX commentary
Dec 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMUX is a StrongBuy and RGNX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 26, 2025
Stock price -- (IMUX: $0.58 vs. RGNX: $14.46)
Brand notoriety: IMUX and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMUX: 58% vs. RGNX: 31%
Market capitalization -- IMUX: $70.28M vs. RGNX: $732.01M
IMUX [@Biotechnology] is valued at $70.28M. RGNX’s [@Biotechnology] market capitalization is $732.01M. The market cap for tickers in the [@Biotechnology] industry ranges from $117.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMUX’s FA Score shows that 0 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • IMUX’s FA Score: 0 green, 5 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, RGNX is a better buy in the long-term than IMUX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMUX’s TA Score shows that 4 TA indicator(s) are bullish while RGNX’s TA Score has 5 bullish TA indicator(s).

  • IMUX’s TA Score: 4 bullish, 4 bearish.
  • RGNX’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, RGNX is a better buy in the short-term than IMUX.

Price Growth

IMUX (@Biotechnology) experienced а +0.74% price change this week, while RGNX (@Biotechnology) price change was +9.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.88%. For the same industry, the average monthly price growth was +4.46%, and the average quarterly price growth was +55.39%.

Reported Earning Dates

IMUX is expected to report earnings on Feb 19, 2026.

RGNX is expected to report earnings on Mar 03, 2026.

Industries' Descriptions

@Biotechnology (+2.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGNX($732M) has a higher market cap than IMUX($70.3M). RGNX YTD gains are higher at: 87.063 vs. IMUX (-41.570). IMUX has higher annual earnings (EBITDA): -105.37M vs. RGNX (-120M). RGNX has more cash in the bank: 274M vs. IMUX (35.1M). IMUX has less debt than RGNX: IMUX (792K) vs RGNX (76.5M). RGNX has higher revenues than IMUX: RGNX (161M) vs IMUX (0).
IMUXRGNXIMUX / RGNX
Capitalization70.3M732M10%
EBITDA-105.37M-120M88%
Gain YTD-41.57087.063-48%
P/E RatioN/AN/A-
Revenue0161M-
Total Cash35.1M274M13%
Total Debt792K76.5M1%
FUNDAMENTALS RATINGS
IMUX vs RGNX: Fundamental Ratings
IMUX
RGNX
OUTLOOK RATING
1..100
564
VALUATION
overvalued / fair valued / undervalued
1..100
41
Fair valued
73
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
8737
P/E GROWTH RATING
1..100
10020
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMUX's Valuation (41) in the Pharmaceuticals Major industry is in the same range as RGNX (73) in the Biotechnology industry. This means that IMUX’s stock grew similarly to RGNX’s over the last 12 months.

IMUX's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as RGNX (100) in the Biotechnology industry. This means that IMUX’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's SMR Rating (98) in the Biotechnology industry is in the same range as IMUX (100) in the Pharmaceuticals Major industry. This means that RGNX’s stock grew similarly to IMUX’s over the last 12 months.

RGNX's Price Growth Rating (37) in the Biotechnology industry is somewhat better than the same rating for IMUX (87) in the Pharmaceuticals Major industry. This means that RGNX’s stock grew somewhat faster than IMUX’s over the last 12 months.

RGNX's P/E Growth Rating (20) in the Biotechnology industry is significantly better than the same rating for IMUX (100) in the Pharmaceuticals Major industry. This means that RGNX’s stock grew significantly faster than IMUX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IMUXRGNX
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
Momentum
ODDS (%)
Bearish Trend 4 days ago
88%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
76%
Declines
ODDS (%)
Bearish Trend 8 days ago
86%
N/A
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
69%
View a ticker or compare two or three
Interact to see
Advertisement
IMUX
Daily Signal:
Gain/Loss:
RGNX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DTCFF0.600.06
+10.35%
DEFENCE THERAPEUTICS INC
BENZF1.160.10
+9.43%
Benz Mining Corp
CHJTF0.95N/A
N/A
CSPC Pharmaceuticals Group Ltd.
NCTKY11.50N/A
N/A
Nabtesco Corp.
PLDGP55.13N/A
N/A
Prologis, Inc.

IMUX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMUX has been loosely correlated with PLRX. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if IMUX jumps, then PLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMUX
1D Price
Change %
IMUX100%
+1.78%
PLRX - IMUX
36%
Loosely correlated
+1.65%
ERAS - IMUX
35%
Loosely correlated
+1.18%
ORIC - IMUX
34%
Loosely correlated
+1.93%
REVB - IMUX
29%
Poorly correlated
+1.15%
RGNX - IMUX
29%
Poorly correlated
+0.77%
More

RGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with VYGR. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then VYGR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
+0.77%
VYGR - RGNX
56%
Loosely correlated
+2.01%
SYRE - RGNX
56%
Loosely correlated
-0.54%
BEAM - RGNX
55%
Loosely correlated
+1.33%
DNLI - RGNX
53%
Loosely correlated
+1.07%
XNCR - RGNX
53%
Loosely correlated
-0.13%
More